Card image cap
CDSCO expert committee nod to Novo Nordisk for semaglutide study

The Subject Expert Committee (SEC) of India’s Central Drugs Standard Control Organization (CDSCO) has given its recommendation to Novo Nordisk’s trial of the anti-diabetic drug semaglutide in India. Semaglutide,  a glucagon-like peptide 1 (GLP 1) analog used to manage type 2 diabetes along with lifestyle changes such as dietary management and optimum physical activity, was approved by the FDA for subcutaneous injection as early as 2017. The Danish insulin maker justified that the international clinical trials have determined the drug’s efficacy in reducing glycosylated hemoglobin (HbA1c) levels and body weight, and the SEC’s recommendation is based on this submission. 

Content by Future Medicine

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.


Supported by Koye Pharmaceuticals

Submit a Comment